Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 17Cisplatin 11Carboplatin 9Cyclophosphamide 8fludarabine 6Paclitaxel 6Nivolumab 6Bevacizumab 6aldesleukin 5Radiotherapy 5toripalimab 4tisotumab vedotin 4fludarabine phosphate 4Topotecan 4Interleukin-2 4Docetaxel 4Brachytherapy 4spartalizumab 3Ipilimumab 3Fulvestrant 3ferumoxtran-10 2enzalutamide 2durvalumab 2cemiplimab 2bemarituzumab 2balstilimab 2Trastuzumab 2Radiation 2Magnetic Resonance Spectroscopy 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Uterine Cervical Neoplasms × NHS-IL12 immunocytokine × Clear all
NCT04287868 2026-04-13

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
51 enrolled 16 charts
GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡